(The study has not yet been published in a peer-reviewed journal.) A comparable study hasnt been done with oral Wegovy, but Novo Nordisk, the company that manufactures the drug, believes that patients should be able to switch from the Wegovy shot without affecting their weight
diabetes, or a combination of both, the study noted
Although these results hint at potential beyond-weight reproductive benefits (83), the extremely small sample size ( n = 28), open-label design, and lack of objective measurements for key biological intermediates (e.g., oocyte/embryo quality and endometrial receptivity), combined with controversies over the adequacy of the washout period, mean these conclusions should be viewed as exploratory rather than definitive
It was apparent that 100 nM dulaglutide raise force of contraction in HAP compared to pre-drug value (Ctr)
Mice were monitored for clinical abnormalities ( Supplemental Table 6 )